Get started
Author

Francesco Jacopo Romano

Observed names: F J Romano, F.J. Romano, FRANCESCO JACOPO ROMANO, Francesco Romano, Romano, Francesco Jacopo
ORCID: 0000-0002-2361-2486
Observed ORCID: 0000-0002-2361-2486
OpenAlex ID: A5042804413
Micrornas in prostate cancer: an overview
2017 · Daniela Vanacore, Mariarosaria Boccellino, et al. · Oncotarget · 140
PDF
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences
2017 · Vincenzo Quagliariello, Sabrina Rossetti, et al. · Oncotarget · 76
PDF
Retrograde intra renal surgery versus percutaneous nephrolithotomy for renal stones >2 cm. A systematic review and meta-analysis
2020 · Biagio Barone, Felice Crocetto, et al. · Minerva Urologica e Nefrologica · 54
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review
2016 · Francesco Jacopo Romano, Sabrina Rossetti, et al. · Oncotarget · 34
PDF
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab
2022 · FRANCESCO JACOPO ROMANO, RICCARDO RONGA, et al. · Cancer Diagnosis & Prognosis · 32
PDF
Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis
2017 · Rossella Di Franco, Valentina Borzillo, et al. · Oncotarget · 31
PDF
Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment
2017 · Rossella Di Franco, Valentina Borzillo, et al. · The Neuroradiology Journal · 30
Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?
2014 · Alfonso De Stefano, Roberto Moretto, et al. · Clinical Colorectal Cancer · 24
ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: A clinicopathologic study
2018 · Francesco Jacopo Romano, Elia Guadagno, et al. · Journal of Cellular Biochemistry · 18
Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.
2017 · R Di Franco, V Borzillo, et al. · PubMed · 15
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results
2023 · Filippo Lococo, Alessandra Cancellieri, et al. · Clinical Lung Cancer · 14
PDF
The outcomes of salvage surgery for non-small cell lung cancer after immune checkpoint inhibitor or targeted therapy treatment. A multi-center international real-life study
2025 · Francesco Guerrera, Filippo Lococo, et al. · European Journal of Surgical Oncology · 13
PDF
Sarcomatoid larynx carcinoma differential clinical evolution, on field statistical considerations
2021 · Filippo Ricciardiello, Marco Bocchetti, et al. · American Journal of Otolaryngology · 6
ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review
2017 · Gerardo Botti, Maria Gabriella Malzone, et al. · International Journal of Medical Sciences · 5
PDF
Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?
2026 · Paolo Maione, Francesco Jacopo Romano, et al. · Current Oncology · 4
PDF
Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences
2017 · Vincenzo Quagliariello, Sabrina Rossetti, et al. · Oncotarget · 4
PDF
From Transcription Factors Dysregulation to Malignancy: In Silico Reconstruction of Cancer’s Foundational Drivers—The Eternity Triangle
2025 · Anna Lisa Cammarota, Albino Carrizzo, et al. · International Journal of Molecular Sciences · 2
PDF
Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study
2021 · Francesco Jacopo Romano, Carmela Barbato, et al. · Oncotarget · 1
Correction: Maione et al. Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? Curr. Oncol. 2026, 33, 54
2026 · Paolo Maione, Francesco Jacopo Romano, et al. · Current Oncology
PDF
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study
2026 · Giulia Pasello, Claudia Proto, et al. · Frontiers in Oncology
PDF
EP.11.03 First Line Chemo-Immunotherapy Prognostic Factors Predicting Non Small Cell Lung Cancer Overall Survival
2025 · R. Ronga, F. Vitiello, et al. · Journal of Thoracic Oncology
44P: First-line chemo-immunotherapy prognostic factors predicting non-small cell lung cancer (NSCLC) overall survival: Multicentric observational study
2025 · R. Ronga, F. Vitiello, et al. · Journal of Thoracic Oncology
PDF
Prognostic relevance of Platelet-to-Lymphocyte Ratio in patients with Muscle-Invasive Bladder Cancer Patients: real world data from a retrospective multicenter analysis
2023 · G. Pecoraro, S. Scagliarini, et al. · European Urology Open Science
13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumab
2021 · F.J. Romano, C. Barbato, et al. · Annals of Oncology
Chapter 3: Surgical Management of Liver Metastases from Gastric Cancer
2018 · Fabio Uggeri, Enrico Pinotti, et al. · BOA (University of Milano-Bicocca)
Works count: 28
Citation count: 503
H-index: 12
I10-index: 12
Year
Topic
Type